NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial
Colette J. Shen(University of North Carolina at Chapel Hill), Tanguy Y. Seiwert(Georgetown University), Jiaxin Niu(The University of Texas MD Anderson Cancer Center), Ari J. Rosenberg(University of Chicago), K. Jameson, J.J. Caudell(Moffitt Cancer Center), J. Weiß(University of North Carolina at Chapel Hill), Patricia Said(Nanobiotix (France)), Jessica M. Frakes(Moffitt Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
October 25, 2021
Cited by 1
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653